SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 206 filers reported holding SANGAMO THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.70 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $33,943 | -53.6% | 56,544 | 0.0% | 0.00% | – |
| Q2 2023 | $73,224 | -25.4% | 56,544 | 0.0% | 0.00% | – |
| Q1 2023 | $98,104 | -38.3% | 56,544 | +8.1% | 0.00% | – |
| Q4 2022 | $158,980 | -39.3% | 52,297 | 0.0% | 0.00% | – |
| Q3 2022 | $262,000 | +40.1% | 52,297 | +15.6% | 0.00% | – |
| Q2 2022 | $187,000 | +98.9% | 45,238 | +184.3% | 0.00% | – |
| Q1 2022 | $94,000 | -53.5% | 15,914 | -28.2% | 0.00% | – |
| Q3 2021 | $202,000 | +16.1% | 22,158 | +100.8% | 0.00% | – |
| Q4 2020 | $174,000 | -55.9% | 11,036 | -75.0% | 0.00% | -100.0% |
| Q2 2020 | $395,000 | +98.5% | 44,086 | +37.6% | 0.00% | – |
| Q1 2020 | $199,000 | -31.6% | 32,038 | +5.0% | 0.00% | -100.0% |
| Q1 2019 | $291,000 | -61.3% | 30,500 | -53.4% | 0.00% | 0.0% |
| Q4 2018 | $752,000 | +1988.9% | 65,508 | +447.7% | 0.00% | – |
| Q4 2016 | $36,000 | – | 11,961 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alexandria Capital, LLC | 1,003,725 | $15,663,000 | 1.66% |
| Golden State Equity Partners | 123,817 | $1,932,000 | 1.33% |
| Rhenman & Partners Asset Management AB | 821,888 | $12,826,000 | 1.05% |
| WASATCH ADVISORS LP | 10,072,381 | $157,180,000 | 0.77% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 29,636 | $462,000 | 0.73% |
| Ceeto Capital Group, LLC | 80,000 | $1,248,000 | 0.63% |
| EMC Capital Management | 48,992 | $765,000 | 0.58% |
| Fort Sheridan Advisors LLC | 71,173 | $1,111,000 | 0.54% |
| Vanguard Capital Wealth Advisors | 34,680 | $584,000 | 0.54% |
| Casdin Capital, LLC | 1,080,000 | $16,853,000 | 0.50% |